Case Report
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Apr 16, 2023; 11(11): 2528-2534
Published online Apr 16, 2023. doi: 10.12998/wjcc.v11.i11.2528
Prostate-specific antigen reduction after capecitabine plus oxaliplatin chemotherapy: A case report
Qian Zou, Rui-Lin Shen, Xiao Guo, Chen-Ye Tang
Qian Zou, Jiaxing University Master Degree Cultivation Base, Zhejiang Chinese Medical University, Hangzhou 310000, Zhejiang Province, China
Rui-Lin Shen, Xiao Guo, Chen-Ye Tang, Department of Urology, The Second Affiliated Hospital of Jiaxing University, Jiaxing 314001, Zhejiang Province, China
Author contributions: Tang CY conceived the idea; Zou Q collected data and drafted the manuscript; Shen RL and Guo X have reviewed the manuscript; All authors read and approved the final draft of the manuscript.
Supported by Jiaxing Science and Technology Foundation, No. 2021AY30018.
Informed consent statement: Written informed consent was obtained from all the patients.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Chen-Ye Tang, Doctor, Department of Urology, The Second Affiliated Hospital of Jiaxing University, No. 1518 Huancheng Bei Lu, Nanhu District, Jiaxing 314001, Zhejiang Province, China. john99233@126.com
Received: December 21, 2022
Peer-review started: December 21, 2022
First decision: January 20, 2023
Revised: February 1, 2023
Accepted: March 20, 2023
Article in press: March 20, 2023
Published online: April 16, 2023
Processing time: 105 Days and 20.5 Hours
Core Tip

Core Tip: Chemotherapy is mainly used for castration-resistant prostate cancer (PC) (CRPC) and may also benefit patients with PC who have not progressed to CRPC. We describe a patient with high-risk locally advanced PC treated with laparoscopic radical prostatectomy plus short-term adjuvant hormonal therapy and rectal cancer treated with laparoscopic radical rectal resection plus adjuvant chemotherapy, and found that prostate-specific antigen declined after the capecitabine plus oxaliplatin chemotherapy.